CLSI AST Bad Bacteria Webinar
Breaking Bad Bacteria: Mastering the 2024 CLSI Antimicrobial Susceptibility Testing Updates
This on-demand webinar is a collaboration between Clinical and Laboratory Standards Institute (CLSI), Society of Infectious Disease Pharmacists (SIDP), and the American College of Clinical Pharmacists (ACCP). It provides updates on the latest breakpoint recommendations from CLSI M100 | Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition, and offers practical strategies on incorporating those changes into clinical practice. Speakers address the importance of partnerships between pharmacists and laboratory professionals on effective implementation of updates to enhance clinical practice.
SIDP and ACCP ID PRN members, please?register on SIDP's website.
Target Audience: This activity was planned to meet the educational needs of pharmacists and laboratory professionals.
{{FormatPrice(currentPrice)}}
Free
{{FormatPrice(nonMemberPrice)}} List PriceLearning Objectives
- Summarize highlights from CLSI M100—Performance Standards for Antimicrobial Susceptibility Testing, 34th?Edition standards for antimicrobial susceptibility testing (AST) and reporting.
- Examine nuances that may be encountered when performing (AST) for carbapenem-resistant bacteria.
- Evaluate species-specific guidance for AST of Staphylococcus?sp. and ceftriaxone dosing guidance for methicillin-susceptible?Staphylococcus aureus.
- Discuss the revised breakpoints, reporting, and treatment recommendations for?Stenotrophomonas maltophilia
Advanced: Highly technical. For those with current skills/knowledge and extensive experience in a specialty area.
CLSI is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
Learning Objectives
- Summarize highlights from CLSI M100—Performance Standards for Antimicrobial Susceptibility Testing, 34th?Edition standards for antimicrobial susceptibility testing (AST) and reporting.
- Examine nuances that may be encountered when performing (AST) for carbapenem-resistant bacteria.
- Evaluate species-specific guidance for AST of Staphylococcus?sp. and ceftriaxone dosing guidance for methicillin-susceptible?Staphylococcus aureus.
- Discuss the revised breakpoints, reporting, and treatment recommendations for?Stenotrophomonas maltophilia
Advanced: Highly technical. For those with current skills/knowledge and extensive experience in a specialty area.
CLSI is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.